Form 4: Vanda Pharmaceuticals Director Phaedra Chrousos Reports Acquisition of Stock Options and Restricted Stock Units

Director Phaedra Chrousos reports acquisition of stock options and restricted stock units in Vanda Pharmaceuticals.

Summary

• On May 22, 2024, Phaedra Chrousos, a director of Vanda Pharmaceuticals Inc., reported the acquisition of 21,887 shares of common stock underlying a time-based restricted stock unit (RSU) award.
• These RSUs will vest on May 22, 2025, contingent upon continuous service to the Issuer through the vesting date.
• Chrousos also acquired options to purchase 40,202 shares of common stock at an exercise price of $5.14 on the same date.
• These options vest and become exercisable with respect to 100% of the option shares on May 22, 2025, also contingent upon continuous service to the Issuer through the vesting date.
• Following the reported transaction, Chrousos beneficially owns 64,125 shares of common stock and 40,202 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard transaction of stock options and RSUs, indicating alignment of the director's interests with the company's performance.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the director's continuous service to the company through May 22, 2025.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the compensation and equity ownership of company directors.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates